Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
André J Scheen. (2020) Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety 19:3, pages 243-256.
Read now
Read now
Articles from other publishers (14)
Asimah Khalid & Imrana Naseem. (2023) Increased therapeutic effect of nanotized silibinin against glycation and diabetes: An in vitro and in silico-based approach. Biochimica et Biophysica Acta (BBA) - General Subjects 1867:7, pages 130364.
Crossref
Crossref
Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, An-Shun Tai, Shih-Chen Fu, Szu-Tah Chen & Sheng-Hsuan Lin. (2022) Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabetes Research and Clinical Practice 186, pages 109816.
Crossref
Crossref
Justin T. CallPedro CortésDana M. Harris. (2022) A practical review of diabetes mellitus type 2 treatment in primary care. Romanian Journal of Internal Medicine 60:1, pages 14-23.
Crossref
Crossref
Xin Wei, Yu Bai, Zhuo Wang, Xiaohong Zheng, Zening Jin & Xin Liu. (2021) Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 13:1.
Crossref
Crossref
Qing Li, Xiaoyan Deng, Neng Jiang, Liuwei Meng, Junhao Xing, Weizhe Jiang & Yanjun Xu. (2021) Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry 225, pages 113765.
Crossref
Crossref
Jong-Mi Seong, Jong Joo Kim, Hae Jin Kim & Hyun Soon Sohn. (2021) Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Crossref
Enrico Longato, Benedetta Maria Bonora, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro & Gian Paolo Fadini. (2021) Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. Diabetes Research and Clinical Practice 179, pages 109024.
Crossref
Crossref
Zhinan Xiang, Haifei Xie, Qilin Tong, Jun Pan, Luosheng Wan, Jinbo Fang & Jiachun Chen. (2021) Revealing hypoglycemic and hypolipidemic mechanism of Xiaokeyinshui extract combination on streptozotocin-induced diabetic mice in high sucrose/high fat diet by metabolomics and lipidomics. Biomedicine & Pharmacotherapy 135, pages 111219.
Crossref
Crossref
Mohamed Hassanein, Alaaeldeen Bashier, Hoosen Randeree, Megahed Abouelmagd, Waleed AlBaker, Bachar Afandi, Omar Abu Hijleh, Inass Shaltout, Magdy EI-Sharkawy, Selcuk Dagdelen & Samir Assaad Khalil. (2020) Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes Research and Clinical Practice 169, pages 108465.
Crossref
Crossref
Raffaele Napoli, Gloria Formoso, Salvatore Piro, Giovanni Targher, Agostino Consoli & Francesco Purrello. (2020) Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases 30:11, pages 1926-1936.
Crossref
Crossref
Zheng Li, Zongtao Zhou, Lijun Hu, Liming Deng, Qiang Ren & Luyong Zhang. (2020) ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacological Research 159, pages 105035.
Crossref
Crossref
Sheng Tang, Can Wang, Ying–Hong Li, Tian–Yu Niu, Yuan–Hui Zhang, Yu–Dong Pang, Yan–Xiang Wang, Wei–Jia Kong & Dan–Qing Song. (2020) Structure–activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy. European Journal of Medicinal Chemistry 201, pages 112315.
Crossref
Crossref
Mao-Bing Chen, Rui-Jun Xu, Qi-Han Zheng, Xu-Wen Zheng & Hua Wang. (2020) Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus. Medicine 99:33, pages e20875.
Crossref
Crossref
Alberto Llobat, Raquel Román, Natalia Mateu, Daniel M. Sedgwick, Pablo Barrio, Mercedes Medio-Simón & Santos Fustero. (2019) The Fluoro-Pauson–Khand Reaction in the Synthesis of Enantioenriched Nitrogenated Bicycles Bearing a Quaternary C–F Stereogenic Center. Organic Letters 21:18, pages 7294-7297.
Crossref
Crossref